DEVELOPING AN ULTRA-FAST READER DEVICE FOR LUNG CANCER DIAGNOSIS

OUR TECHNOLOGY

01 / FAST

A faster diagnosis increases the chance of patients survival.

Early diagnosis of lung cancer increases the survival rates by over 1000%.

FLEET is an ultra-fast reader device able to give results in 50 min, while 2 weeks is required with the current methods for receiving diagnosis.

02 / ACCURATE

In cancer diagnostics, even 1% error matters.

FLEET reduces the error rate of current techniques from 7-15% to 2-3%. Moreover, our technology specificity is 99%, while other methods have 84-97% specificity.

The current methods generate delays and false diagnosis. However, the expected survival rate of patients improves over 300% with FLEET technology

03 / CHEAPER

Cancer diagnostic has a really high cost for every single country.

Denmark alone spends over 2 bill DKK annually on ineffective prevention of cancer.

It is estimated that the current cost of this diagnostic is 1,550 USD patient/month. However, FLEET is a cheaper alternative with an estimated cost of 250-600 USD patient/month.

Allowing savings over 6-fold (up to 7.200 USD patient/year; Stanford University Hospital data, 2017).

Product

MEET FLEET

OUR STORY

FLEET is the result of 10 years of research within synthesis of ultra-specific oligonucleotides and
their application in fluorescence-based nucleic acid diagnostics.

This project is part of the research work of DTU Chemistry in Kira Astakhova group.

FLEET also counts with the current support and collaboration of different companies and hospitals, as well as advisors and clinical support.

OUR VISION

FLEET has the purpose of tackling the lack of specificity, high cost and slow diagnosis of lung cancer with the current methods that are used.

Our main goal is to be able to increase patients rate survival with an early and accurate diagnosis of the disease.

Moreover, we expect our technology to be used for the diagnosis of other types of cancer apart of lung cancer.

OUR TECHNOLOGY

FLEET has three main products:

Microfluidic chip in which patient blood is applied.

Reader device that measures fluorescence outcome inside the chip

Software for handling the fluorescence
data from the reader.

Inside the chip a sequential hybridization of DNA target to our capture probe, and then annealing of a signal "booster" take place.

Specificity and sensitivity of FLEET are obtained through rationally designed oligonucleotide probes within the chip and our unique ultra-bright fluorescence “booster”.

The read out is a simple fluorescence signal.

About